112 related articles for article (PubMed ID: 2205334)
1. Phase II trial of methylglyoxal-bis(guanylhydrazone) (MGBG) in patients with refractory multiple myeloma: an Eastern Cooperative Oncology Group (ECOG) study.
Winter JN; Ritch PS; Rosen ST; Oken MM; Wolter JM; Wiernik PH; O'Connell MJ
Cancer Invest; 1990; 8(2):143-6. PubMed ID: 2205334
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of methylglyoxal bis-guanylhydrazone (MGBG) in refractory small cell lung cancer.
Simon MS; Eckenrode J; Natale RB
Invest New Drugs; 1990; 8 Suppl 1():S79-81. PubMed ID: 2166008
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of methylglyoxal bis (guanylhydrazone) (MGBG) in advanced head and neck cancer.
Forastiere AA; Natale RB; Wheeler RR
Cancer; 1986 Dec; 58(12):2585-8. PubMed ID: 3779608
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of cisplatin and methylglyoxal bis-guanylhydrazone (MGBG) in recurrent squamous cell carcinoma of the head and neck.
Takasugi BJ; Perry DJ; Wheeler RH; Forastiere AA
Am J Clin Oncol; 1986 Aug; 9(4):299-301. PubMed ID: 3751967
[TBL] [Abstract][Full Text] [Related]
5. Alterations in bone marrow and blood mononuclear cell polyamine and methylglyoxal bis(guanylhydrazone) levels: phase I evaluation of alpha-difluoromethylornithine and methylglyoxal bis(guanylhydrazone) treatment of human hematological malignancies.
Maddox AM; Freireich EJ; Keating MJ; Haddox MK
Cancer Res; 1988 Mar; 48(5):1367-73. PubMed ID: 3124958
[TBL] [Abstract][Full Text] [Related]
6. Polyamines increase in human peripheral blood and bone marrow mononuclear cells following administration of methylglyoxal bis(guanylhydrazone).
Maddox AM; Keating MJ; Freireich EJ; Haddox MK
Chemotherapy; 1988; 34(5):419-29. PubMed ID: 3141118
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of methyl-glyoxal bis-guanylhydrazone (NSC 3296) in advanced ovarian cancer.
Vogl SE; Pagano M; Horton J
Am J Clin Oncol; 1984 Dec; 7(6):733-6. PubMed ID: 6528867
[TBL] [Abstract][Full Text] [Related]
8. Methylglyoxal-bis(guanylhydrazone) in hormone-resistant adenocarcinoma of the prostate.
Scher HI; Yagoda A; Ahmed T; Watson RC
J Clin Oncol; 1985 Feb; 3(2):224-8. PubMed ID: 3968552
[TBL] [Abstract][Full Text] [Related]
9. Inefficacy of methylglyoxal bis(guanylhydrazone) (MGBG) in patients with recurrent head and neck squamous cell carcinoma.
Arteaga CL; Clark GM
Invest New Drugs; 1989 Jul; 7(2-3):281-3. PubMed ID: 2793385
[No Abstract] [Full Text] [Related]
10. Phase I trial of alpha-difluoromethyl ornithine (DFMO) and methylglyoxal bis (guanylhydrazone) (MGBG) in patients with advanced prostatic cancer.
Herr HW; Warrel RP; Burchenal JH
Urology; 1986 Dec; 28(6):508-11. PubMed ID: 3097903
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of alpha-difluoromethylornithine and methyl-GAG.
Splinter TA; Romijn JC
Eur J Cancer Clin Oncol; 1986 Jan; 22(1):61-7. PubMed ID: 3082642
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of [14C]methylglyoxal-bis-guanylhydrazone) in patients with leukemia.
Rosenblum MG; Keating MJ; Yap BS; Loo TL
Cancer Res; 1981 May; 41(5):1748-50. PubMed ID: 7214342
[TBL] [Abstract][Full Text] [Related]
13. Phase II trials of methylglyoxal-bis (guanylhydrazone).
Kelsen DP; Yagoda A; Warrell R; Chapman R; Whittes R; Gralla RJ; Casper E; Young CW
Am J Clin Oncol; 1982 Apr; 5(2):221-5. PubMed ID: 7046414
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of methylglyoxal-bis-guanylhydrazone by alpha-difluoromethylornithine in rat prostate cancer.
Herr HW; Kleinert EL; Relyea NM; Whitmore WF
Cancer; 1984 Mar; 53(6):1294-8. PubMed ID: 6420041
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of methylglyoxal-bis-(guanylhydrazone) in non-small-cell lung cancer.
Chapman R; Kelsen D; Gralla R; Itri L; Casper E; Young C; Golbey R
Cancer Clin Trials; 1981; 4(4):389-91. PubMed ID: 6274532
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of methylglyoxal-bis-guanylhydrazone (methyl-GAG) in patients with soft-tissue sarcomas.
Sordillo PP; Magill GB; Welt S
Am J Clin Oncol; 1985 Aug; 8(4):316-8. PubMed ID: 3909804
[TBL] [Abstract][Full Text] [Related]
17. Modification of uptake and antiproliferative effect of methylglyoxal bis(guanylhydrazone) by treatment with alpha-difluoromethylornithine in rodent cell lines with different sensitivities to methylglyoxal bis(guanylhydrazone).
Alhonen-Hongisto L; Levin VA; Marton LJ
Cancer Res; 1985 Feb; 45(2):509-14. PubMed ID: 3917847
[TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of MGBG in non-small cell carcinoma of the lung. A Southwest Oncology Group study.
Vance RB; Knight WA; Chen TT; Costanzi JJ; LoBuglio AF
Invest New Drugs; 1983; 1(1):89-93. PubMed ID: 6678859
[TBL] [Abstract][Full Text] [Related]
19. Comparison of specificity of inhibition of polyamine synthesis in bovine lymphocytes by ethylglyoxal bis(guanylhydrazone) and methylglyoxal bis(guanylhydrazone).
Igarashi K; Porter CW; Morris DR
Cancer Res; 1984 Nov; 44(11):5326-31. PubMed ID: 6488187
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of bleomycin, chlorozotocin, MGBG, and bruceantin in patients with advanced soft tissue sarcoma, bone sarcoma, or mesothelioma.
Amato DA; Borden EC; Shiraki M; Enterline HT; Rosenbaum C; Davis HL; Paul AR; Stevens CM; Lerner HJ
Invest New Drugs; 1985; 3(4):397-401. PubMed ID: 2417985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
